IMVT
Immunovant, Inc.
$28.94
+6.32%
2026-05-08
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Key Fundamentals
Forward P/E
-10.72
EPS (TTM)
$-2.67
ROE
-69.3%
Profit Margin
0.0%
Price/Book
5.71
Beta
0.70
Market Cap
$5.64B
Avg Volume (10D)
1.4M
Recent Breakout Signals
No recent breakout signals detected for IMVT.
Recent Price Range (60 Days)
60D High
$30.09
60D Low
$22.79
Avg Volume
1.3M
Latest Close
$28.94
Get breakout alerts for IMVT
Sign up for Breakout Scanner to receive daily notifications when IMVT triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Immunovant, Inc. (IMVT) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMVT daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMVT operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.